Johnson & Johnson (JNJ)
NYSEHealth CareDrug Manufacturers - GeneralSnapshot 2026-07-07
$267.34+3.09%
Close 2026-07-07 · 1-day change
Reading JNJ? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track JNJ free→NYSEHealth CareDrug Manufacturers - GeneralSnapshot 2026-07-07
Reading JNJ? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track JNJ free→A long-form read on the 1–3 year hold thesis. Slower and deeper than the daily snapshot — it refreshes only when the evidence moves.
This investment represents a durable compounder with a focus on steady revenue and earnings growth. The current thesis state is stable, supported by recent strong financial performance and management's commitment to increasing guidance.
The market appears to price in an elevated valuation, reflecting a premium compared to peers. However, there is an expectations gap, indicating that some investors may see the current valuation as unjustified given recent execution quality concerns.
Management has been successful in increasing revenue and earnings guidance, which supports a positive fundamental trajectory. Although the near-term risk of missing guidance is low, the company has faced challenges in recent quarters, which could affect confidence.
The long-term thesis hinges on the performance of sector bellwethers like LLY, ABBV, and MRK. If these companies continue to perform well, it could support JNJ's momentum; however, any negative guidance from them could pose risks.
Overall, JNJ's fundamentals and management execution appear solid for the next 1 to 3 years, but sector performance will be crucial. Not investment advice.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. The latest earnings beat and the increase in 2026 revenue guidance to $100.8 billion support this improved outlook. There are no current threats impacting the thesis.
as of 2026-07-07
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Why it matters: Earnings results will show if Johnson & Johnson is on track to meet its revenue and EPS guidance for 2026.
Confirms one read:Reported sales growth of at least 7% year over year, aligning with the $100.8B guidance.
Confirms the other:Sales growth is under 5% compared to last year. This shows possible problems in meeting goals.
Why it matters: An increase in revenue guidance shows strong growth momentum for Johnson & Johnson.
Confirms:Management confirms Q2 revenue guidance raised to $100.8B or higher.
Disproves:Management expects revenue to be less than $100.8B.
Why it matters: Higher EPS guidance shows better earnings and more confidence from investors.
Confirms:Management raises Q2 EPS guidance to $11.55 or more.
Disproves:Management keeps EPS guidance under $11.55.
Why it matters: A confirmed dividend increase shows that the company uses its money well. It also rewards shareholders.
Confirms:The company pays the increased dividend of $1.34 per share on June 9, 2026.
Disproves:The company does not pay the increased dividend as announced.
Why it matters: If revenue growth slows, it could signal trouble in the healthcare sector. This may worry investors.
Confirms:Revenue growth falls below the median growth rate for the sector.
Disproves:Revenue growth remains at or above the median growth rate.
Why it matters: Hitting sales goals will show how valuable the Abiomed purchase is for JNJ's growth.
Confirms:Abiomed's net sales are over $3.7 billion in the second quarter of 2027.
Disproves:Abiomed's net sales do not reach the $3.7 billion threshold during the specified period.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.